Acute Immune Signatures And Their Legacies In COVID-19 Infec
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
Patients with cancer, particularly those with solid tumors, mounted an immune response to COVID-19 similar to that seen in people without cancer, but among patients with hematologic cancers, immune responses were less pronounced and were highly variable, typically taking longer to clear the virus.

This study involved 76 patients with cancer; 41 of these patients had COVID-19, and 35 served as non-COVID cancer control patients. Peripheral blood was collected from all patients; multiple samples were taken every 2 to 4 days where possible.

Both groups were matched for age, body mass index, and tumor type, and both included patients with solid and hematologic cancers. They were also comparable in terms of the proportion of patients with stage IV disease, those who received palliative as opposed to radical treatment, and patients who were treated within 4 weeks of recruitment to the study.

The results showed that 24.4% of cancer patients remained asymptomatic; 21.9% had the mild disease; 31.7%, moderate disease; and 21.9%, severe disease. Patients with hematologic cancers were more likely to experience dyspnea than those with solid tumors, and 39% received corticosteroid/antiviral therapies that specifically targeted COVID-19 infection.

Further analysis revealed differences in immune signatures between patients with solid cancers who had active SARS-CoV-2 infection and noninfected control patients. Approximately 75% of patients had detectable antibodies against COVID-19. However, patients with solid tumors showed earlier seroconversion than those with hematologic cancers.